Related Experiment Video

Updated: May 14, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Allelic expression imbalance of JAK2 V617F mutation in BCR-ABL negative myeloproliferative neoplasms

Hye-Ran Kim1, Hyun-Jung Choi, Yeo-Kyeoung Kim

  • 1Brain Korea 21 Project, Center for Biomedical Human Resources, Chonnam National University, Gwangju, South Korea.

Plos One
|January 26, 2013
PubMed

Insights

Allelic expression imbalance of the JAK2 V617F mutation contributes to the diverse phenotypes observed in myeloproliferative neoplasms (MPNs). This finding explains how a single mutation leads to varied MPN subtypes.

Area of Science:

  • Hematology
  • Molecular Biology
  • Genetics

Background:

  • The JAK2 V617F mutation is a key driver in BCR-ABL-negative myeloproliferative neoplasms (MPNs).
  • Understanding the mechanisms behind MPN phenotypic diversity is crucial for diagnosis and treatment.
  • The precise contribution of a single JAK2 mutation to varied MPN presentations remains incompletely understood.

Purpose of the Study:

  • To investigate the role of allelic expression imbalance in the JAK2 V617F mutation.
  • To determine if variations in JAK2 V617F allele expression contribute to the phenotypic diversity of MPNs.

Main Methods:

  • Quantitative analysis of JAK2 V617F mutant allele proportions in RNA and genomic DNA.
  • Comparison of allele expression levels across different MPN subtypes.

Main Results:

  • Significant allelic expression imbalance of the JAK2 V617F mutant was observed.
  • The proportion of the mutant allele was notably higher in RNA compared to genomic DNA.
  • A threefold increase in mutant allele expression was found in essential thrombocythemia, and a twofold increase in polycythemia vera.

Conclusions:

  • Allelic expression imbalance of JAK2 V617F is a significant factor in MPN pathogenesis.
  • This imbalance provides a mechanism for how a single JAK2 mutation can lead to diverse MPN phenotypes.
  • Further research into allele-specific expression can enhance understanding and management of MPNs.

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...